BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
Keith T. Sowards, M.S. / POSITION TITLE
Clinical Physicists
Department of Radiation Oncology
eRA COMMONS USER NAME
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION / DEGREE
(if applicable) / YEAR(s) / FIELD OF STUDY
University of Kentucky / M.S / 1999 / Health Physics
University of Kentucky / B.S. / 1995 / Physics
A. Positions
August 2002 – PresentClinical Physicist
B. Selected peer-reviewed publications
1.A.S. Meigooni, K. Sowards, M. Soldano: Dosimetric Characteristics of the InterSource 103Palladium Brachytherapy Source. Medical Physics 27(5), 1093-1100 (2000).
2.C. Popescu, J. Wise, K. Sowards, A.S. Meigooni, and G. S. Ibbott: Dosimetric Characteristics of the PharmaSeed TM Model BT-125-1 Source. Medical Physics 27(9), 2174-2281 (2000).
3.Ali S. Meigooni, K. Sowards, D. Gearheart: Experimental Determination of Dosimetric Characteristics of Best 125I Brachytherapy Source. Medical Physics 27(9), 2168-2173 (2000).
4.D. Gearheart, A. Drogin, K. Sowards, A.S. Meigooni, and G.S. Ibbott: Dosimetric Characteristics of a New 125I Brachytherapy Source. Medical Physics 27(10), 2278-2285 (2000).
5.A.S. Meigooni, S.A. Dini, K. Sowards, J.L. Hayes, and A. Al-Otoom: Experimental Determination of the TG-43 Dosimetric Characteristics of EchoSeed™ Model (6733 Brachytherapy Source. Medical Physics 29(6), 939-942 (2002).
6.A. Meigooni, K. Sowards, G. Myron: Evaluation of the QZ Veridose Patient Monitoring Phantom. Medical Dosimetry Journal 29:49-54 (2003).
7.A. Meigooni, G. Myron, K. Sowards: Evaluation of the Veridose Invivo Dosimetry System. Medical Dosimetry 27:29-36 (2002).
8.A.S. Meigooni, M.M. Yoe-Sein, A.Y., Al-Otoom, and K.T. Sowards: Determination of the Dosimetric Characteristics of InterSource 125Iodine Brachytherapy Source. Applied Rad & Isotopes 56:589-599 (2002).
9.Ali S. Meigooni, Joshua Hayes, Hualin Zhang, and Keith Sowards: Experimental Determination of IsoAid ADVANTAGE™ 125I Brachytherapy Source. Medical Physics 29(9):2152-2158 (2002).
10.A.S. Meigooni, Z. Bharucha, M. Yoe-Sein, and K.T. Sowards: Dosimetric characteristics of the Best® double-wall 103Pd brachytherapy source. Med Phys 28(12):2568-2575 (2001).
11.K.T. Sowards, A.S. Meigooni: A Monte Carlo evaluation of the dosimetric characteristics of the Best ® Model 2301 125I Brachytherapy Source. Applied Radiation and Isotopes 57:327-333 (2002).
12.K.T. Sowards, A.S. Meigooni: A Monte Carlo evaluation of the dosimetric characteristics of the Amersham model 6733 125I brachytherapy source. Brachytherapy Vol. 1(4):227-232 (2002).
13.Erratum: “Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE™ 125I brachytherapy source” [Med. Phys. 29, 2152–2158 (2002)], Med. Phys. 30, 279 (2003).
14.K.T. Sowards: Monte Carlo Dosimetric Characterization of the IsoAid ADVANTAGETM 103Pd Brachytherapy Source. Journal of the American College of Medical Physics, Vol 8, No 2, (2007).
15. K.T. Sowards, C.M. Luerman, A.S. Meigooni: Evaluation of the dose distribution for
prostate implants using various 125I and 103Pd sources. Med Phys 36(4):1452-1458 (2009).